Boehringer Ingelheim
Overview
Boehringer Ingelheim is a research-driven pharmaceutical company that invests in therapeutic innovation through its corporate venture capital arm, the Boehringer Ingelheim Venture Fund (BIVF). The fund focuses on early-stage and seed investments in areas like immuno-oncology, regenerative medicine, infectious diseases, and digital health.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| New Ruipeng Pet Healthcare Group | Sep 2020 | Strategic | Co-investor |
| New Ruipeng Pet Healthcare Group | Sep 2020 | Strategic | Co-investor |
| AgomAb Therapeutics | Mar 2021 | Series B | Co-investor |
| Click Therapeutics | Apr 2026 | Series D | Lead |
| Otto | Aug 2023 | Series B | Co-investor |
For institutional investors. Book with your work email.
Key People
Sebastian Kreuz
Executive Director Investment Manager (BI Venture Fund)
Daphne Openda
People Partner- Southern Africa OPU
Malcolm Eddie
Head Of Global Support - CRO Strategic Partner Management
Nardjess Nawel Laroussi
Specialty Care Therapy Partner
Swati Choudhary
Learning Partner
Edwin Osas
Senior Principal Consultant CIO Advisory
Anupama Roy
Associate Director- Project & Partner Management, Global Pharmacovigilance
Ali M. YOUSIF
Principal Scientist Head of Peptide Laboratory
Annett Keller
Senior Principal Statistician, CMC Statistics
Aradhana ‘Ara’ Gupta
Sr. Principal Pathologist
Azar Omrani
Principal Scientist-Head Of Laboratory
Benno Ehrl
Principal Scientist - Head Of Laboratory
Di Feng
Senior Principal Scientist, Computational Biology, Computational Biology Expert Lead
Eric Simon
Senior Principal Scientist, Computational Biology, Principal Scientist, Computational Biology Bei Boehringer Ingelheim
Frank Buettner
Senior Principal Scientist - Head Of Laboratory
Frank H. Buettner
Senior Principal Scientist - Head Of Laboratory
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Boehringer Ingelheim based?
Boehringer Ingelheim is headquartered in Ingelheim am Rhein, Germany.
When was Boehringer Ingelheim founded?
Boehringer Ingelheim was founded in 1885.
How many portfolio companies does Boehringer Ingelheim have?
Boehringer Ingelheim has 35 portfolio companies in Caplight's dataset.
What are some companies in Boehringer Ingelheim's portfolio?
Portfolio companies visible on Caplight include New Ruipeng Pet Healthcare Group, New Ruipeng Pet Healthcare Group, AgomAb Therapeutics, Click Therapeutics, Otto.
What was Boehringer Ingelheim's most recent investment shown here?
Boehringer Ingelheim's most recent investment in this portfolio sample was in Click Therapeutics in 2026.
What sectors does Boehringer Ingelheim focus on?
Boehringer Ingelheim focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Frontier & Industrial Tech, Enterprise Software, Enterprise Software, Enterprise Software, Enterprise Software, Enterprise Software, Consumer & Commerce, Consumer & Commerce, Consumer & Commerce, Frontier & Industrial Tech, Enterprise Software.
What company stages does Boehringer Ingelheim focus on?
Boehringer Ingelheim typically invests at the Early stage.
What is Boehringer Ingelheim's AUM?
Boehringer Ingelheim's assets under management are estimated between $250.0M and $500.0M.